Diabetes is a disease defined by high blood sugar level, caused by inappropriate functioning of the pancreas (the organ which secretes insulin in the body). Nephropathy means kidney impairment or damage. Diabetic nephropathy is the impairment or damage to the kidneys caused by diabetes. It is a disease which affects the kidney glomerulus and one of the most major issues for diabetic patients. Not only the person with diabetes has to undergo kidney impairment, but also the acute cases of diabetic nephropathy could lead to kidney miscarriage. The disease affects the kidneys in a way that makes it futile. Progressive growth in proteinuria and failure in renal function, hypertension, and high risk of cardiovascular disease are the major side effects of chronic diabetic nephropathy. Blood pressure (BP) control is necessary in minimizing the progression of diabetic nephropathy. Irrespective of the agent used, lower blood pressure in type II diabetics could slow down the start and progression of diabetic nephropathy.
[b]Explore Report Sample at:[/b] https://www.psmarketresearch.com/market-analysis/diabetic-nephropathy-market/report-sample
On the basis of treatment, the global diabetic nephropathy market is segmented by disease modifying therapies into, diuretics, angiotensin-converting enzyme inhibitors, antioxidant inflammation modulator, angiotensin receptor blockers, renin inhibitors, calcium channel blockers, connective tissue growth factor inhibitors, monocyte chemo attractant proteins inhibitor, monocyte chemo attractant proteins inhibitor, G protein-coupled receptors and endothelin (a receptor antagonist).
There are very few symptoms in the initial stages of diabetic nephropathy; however proteinuria, leg swelling, nocturia, nausea/vomiting and high BP are the common signs and symptoms of advanced diabetic nephropathy. Blood pressure control and glycemic control and are the two major treatments used to limit the development of diabetic nephropathy.
[b]To know more visit:[/b] https://www.psmarketresearch.com/market-analysis/diabetic-nephropathy-market
Some of the major competitors in the global diabetic nephropathy market are Novartis AG, Merck & Co., Inc., Pfizer Inc., Abbott India Limited, Sanofi, Eli Lilly and Company, Reata Pharmaceuticals, Inc., Bayer AG, AbbVie Inc., and Mitsubishi Tanabe Pharma Corporation.